WallStreetZenWallStreetZen

NASDAQ: GLYC
Glycomimetics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for GLYC

Based on 1 analyst offering 12 month price targets for Glycomimetics Inc.
Min Forecast
$8.00+396.89%
Avg Forecast
$8.00+396.89%
Max Forecast
$8.00+396.89%

Should I buy or sell GLYC stock?

Based on 1 analyst offering ratings for Glycomimetics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GLYC stock forecasts and price targets.

GLYC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-08-03

1 of 1

Forecast return on equity

Is GLYC forecast to generate an efficient return?
Company
N/A
Industry
-0.69%
Market
30.34%

Forecast return on assets

Is GLYC forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.29%

GLYC revenue forecast

What is GLYC's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$23.7M
Avg 2 year Forecast
$12.8M
Avg 3 year Forecast
$26.9M

GLYC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLYC$1.61$8.00+396.89%Buy
INO$0.38N/AN/A
HOWL$2.90$12.00+313.79%Buy
SLDB$5.06$7.00+38.34%Strong Buy
ANVS$10.28$32.50+216.15%Strong Buy
View Top Biotech Stocks

Glycomimetics Stock Forecast FAQ

Is Glycomimetics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: GLYC) stock is to Buy GLYC stock.

Out of 1 analyst, 0 (0%) are recommending GLYC as a Strong Buy, 1 (100%) are recommending GLYC as a Buy, 0 (0%) are recommending GLYC as a Hold, 0 (0%) are recommending GLYC as a Sell, and 0 (0%) are recommending GLYC as a Strong Sell.

If you're new to stock investing, here's how to buy Glycomimetics stock.

What is GLYC's revenue growth forecast for 2025-2027?

(NASDAQ: GLYC) Glycomimetics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.

Glycomimetics's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast GLYC's revenue for 2025 to be $1,526,121,068, with the lowest GLYC revenue forecast at $109,468,600, and the highest GLYC revenue forecast at $2,942,773,536. On average, 1 Wall Street analysts forecast GLYC's revenue for 2026 to be $824,234,163, with the lowest GLYC revenue forecast at $824,234,163, and the highest GLYC revenue forecast at $824,234,163.

In 2027, GLYC is forecast to generate $1,732,179,609 in revenue, with the lowest revenue forecast at $1,732,179,609 and the highest revenue forecast at $1,732,179,609.

What is GLYC's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: GLYC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.29%.

What is GLYC's Price Target?

According to 1 Wall Street analyst that have issued a 1 year GLYC price target, the average GLYC price target is $8.00, with the highest GLYC stock price forecast at $8.00 and the lowest GLYC stock price forecast at $8.00.

The Wall Street analyst predicted that Glycomimetics's share price could reach $8.00 by Aug 3, 2024. The average Glycomimetics stock price prediction forecasts a potential upside of 396.89% from the current GLYC share price of $1.61.

What is GLYC's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: GLYC) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.